Skip to main content

Displaying 801 - 820 of 1628

FTC Staff Comment Before the Missouri House of Representatives Regarding Missouri House Bills 1481 and 1491

Date
Matter Number
V140009
Staff submitted a comment, in response to a request by Representative Jeanne Kirkton of the Missouri House of Representatives, regarding Missouri House Bills 1481 and 1491. HB 1491 would allow APRNs...

Thermo Fisher Scientific Inc., In the Matter of

Thermo Fisher Scientific Inc. agreed to sell assets to GE Healthcare to settle Federal Trade Commission charges that its proposed $13.6 billion acquisition of Life Technologies Corporation (Life) would likely substantially lessen competition.The FTC complaint alleged that the deal, as it was originally proposed, would have eliminated close competition between Thermo Fisher and Life and substantially increased concentration in the markets for short/small interfering ribonucleic acid (siRNA) reagents, cell culture media, and cell culture sera, enabling the combined firm to raise prices and reduce quality for consumers. The proposed order settling the FTC’s charges requires Thermo Fisher to divest its gene modulation business Dharmacon, which contains the siRNA reagents business, as well as its cell culture media and sera business including the HyClone brand to GE Healthcare, along with all intellectual property and know-how necessary to operate each of the divested businesses.

Type of Action
Administrative
Last Updated
FTC Matter/File Number
131 0134
Docket Number
C-4431